Regenxbio (RGNX) Other Operating Expenses (2014 - 2026)

Regenxbio's Other Operating Expenses history runs 12 years deep, the most recent figure standing at -$72.4 million for Q4 2025.

• In Q4 2025, Other Operating Expenses fell 3466.99% year-over-year to -$72.4 million; the TTM figure through Dec 2025 stood at -$134.9 million (down 527.89% YoY), while the FY2025 annual figure was -$278.3 million, down 982.58% from the prior year.
• Other Operating Expenses for Q4 2025 stood at -$72.4 million, down from $5.8 million in the prior quarter.
• The five-year high for Other Operating Expenses was $38.0 million in Q1 2022, with the low at -$422.8 million in Q4 2022.
• The 5-year median for Other Operating Expenses is $7.9 million (2023), against an average of -$20.1 million.
• The sharpest annual moves came in 2021 and 2025: Other Operating Expenses soared 20008.0% in 2021, then sank 3466.99% in 2025.
• Regenxbio's Other Operating Expenses stood at $15.0 million in 2021, then plunged by 2910.99% to -$422.8 million in 2022, then soared by 86.33% to -$57.8 million in 2023, then surged by 103.72% to $2.2 million in 2024, then tumbled by 3466.99% to -$72.4 million in 2025.
• Business Quant data shows RGNX's Other Operating Expenses at -$72.4 million in Q4 2025, $5.8 million in Q3 2025, and -$71.7 million in Q2 2025.